Telehealth weight-management provider Ozari Health has rolled out Ozari Select, a flat-rate compounded GLP-1 plan available in all 50 states, positioning the offering as one of the more transparent pricing structures in a rapidly crowding GLP-1 telehealth market.
Ozari Select carries a month-to-month price of $235 for compounded tirzepatide and $175 for compounded semaglutide, with the clinician consultation and free shipping bundled into the fee. Critically, the company charges the same rate regardless of dose — a differentiator in a category where many competitors price by titration tier. Patients who commit to longer terms see tirzepatide drop to $199 per month on a quarterly plan, $175 semi-annually, and $140 annually.
Formulation and Pharmacy Transparency
Ozari Select offers a choice of three formulations and routes fulfillment through two named, US-licensed 503A compounding pharmacies. The 503A designation — meaning the pharmacies operate under physician prescription requirements and are regulated by state boards of pharmacy — is a point of regulatory significance as the FDA continues to scrutinize compounded GLP-1 access in the wake of brand-name shortage designations. The disclosure of specific pharmacy partners is relatively uncommon in direct-to-consumer GLP-1 telehealth, where supply-chain opacity has drawn regulatory and journalistic attention.
Market Context
The GLP-1 category has become one of the fastest-growing verticals in the broader weight-management and metabolic health space, with compounded versions of tirzepatide and semaglutide serving as lower-cost entry points for patients priced out of brand-name Mounjaro, Zepbound, Ozempic, and Wegovy. That access window is under pressure: FDA has indicated it may revisit the shortage-based compounding exemptions that currently allow 503A pharmacies to legally produce these peptides. For operators in functional nutrition — from protein and meal-replacement brands to satiety-focused supplement formulators — the GLP-1 wave is reshaping purchase behavior and creating adjacent demand for products that complement weight-loss pharmacotherapy, including high-protein formats, electrolyte and hydration products, and gut-health support.
Ozari's nationwide launch, covering markets including California where some competing telehealth platforms have faced access restrictions, signals the company's confidence in its current compliance posture. The no-membership-fee model and fixed per-dose pricing are structured to reduce friction for patients who may have encountered variable billing from other telehealth platforms.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
Frequently Asked Questions
What's the actual price difference between Ozari Select's semaglutide and tirzepatide?
Semaglutide runs $175/month on a month-to-month plan; tirzepatide is $235/month at the same commitment level. Both prices include the clinician consult and shipping, so there's no hidden tiers — you pay the same rate whether you're on 0.5 mg or a full dose.
How does Ozari's pricing compare to competitors like Ro and Calibrate?
Ozari undercuts most major telehealth players on tirzepatide, particularly if you commit to annual pricing ($140/month). Ro and Calibrate typically charge $199–$299/month for compounded tirzepatide depending on dose; Calibrate's brand-name option runs $350+. Ozari's flat-dose pricing removes the pressure to justify higher tiers.
Why does Ozari disclosing its pharmacy partners matter?
They're using named 503A compounding pharmacies regulated by state boards—not gray-market outsourcing. In a category plagued by supply-chain opacity and FDA scrutiny following brand-name shortage designations, that transparency signals compliance-forward operations and reduces regulatory risk for buyers.
What happens if the FDA tightens compounded GLP-1 rules?
Ozari's 503A pharmacy structure puts them ahead of the compliance curve, but an FDA crackdown on shortage-based compounding exemptions could pressure all compounded players. Ozari's disclosed partnership model gives them better odds of maintaining access than competitors using opaque supply chains.
Is Ozari Select available outside the telehealth model?
No — Ozari Select is telehealth-only, available in all 50 states with clinician consultations included in the flat fee. They fulfill through two US-licensed 503A compounding pharmacies and ship directly to patients.
